These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29287189)

  • 1. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.
    De Placido S; Giuliano M; Schettini F; Von Arx C; Buono G; Riccardi F; Cianniello D; Caputo R; Puglisi F; Bonotto M; Fabi A; Bilancia D; Ciccarese M; Lorusso V; Michelotti A; Bruzzese D; Veneziani BM; Locci M; De Laurentiis M; Arpino G
    Breast; 2018 Apr; 38():86-91. PubMed ID: 29287189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Bachelot T; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Bondarenko I; Paluch-Shimon S; Wardley A; Merot JL; du Toit Y; Easton V; Lindegger N; Miles D;
    Ann Oncol; 2019 May; 30(5):766-773. PubMed ID: 30796821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
    Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot X; Burris H; Petersen JA; Stanzel S; Strasak A; Patre M; Ellis P
    J Clin Oncol; 2017 Jan; 35(2):141-148. PubMed ID: 28056202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
    Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience.
    Dao BD; Ho H; Quintal LN
    J Oncol Pharm Pract; 2016 Apr; 22(2):261-4. PubMed ID: 25802300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
    J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
    Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
    Trials; 2020 May; 21(1):391. PubMed ID: 32381018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
    Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
    Swain SM; Kim SB; Cortés J; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Knott A; Clark E; Ross G; Benyunes MC; Baselga J
    Lancet Oncol; 2013 May; 14(6):461-71. PubMed ID: 23602601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
    Baselga J; Swain SM
    Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
    Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA
    Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
    Stefanou D; Kokkali S; Tripodaki ES; Drizou M; Magou E; Zylis D; Prevezanou M; Kapiris M; Nasi D; Ntokou A; Dede M; Ardavanis A
    Anticancer Res; 2018 Nov; 38(11):6565-6569. PubMed ID: 30396987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
    Tian T; Ye J; Zhou S
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
    Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
    Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
    Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
    N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
    Swain SM; Baselga J; Miles D; Im YH; Quah C; Lee LF; Cortés J
    Ann Oncol; 2014 Jun; 25(6):1116-21. PubMed ID: 24685829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.